Cell Research

August 23, 2012 News / biological Valley BIOON / A lysophosphatidic acid receptor 1 (LPAR1) inhibitor Debio-0719 by inducing cancer cells of mice into hibernation to inhibit tumor metastasis, Research Papers in the August 21 issue of the Journal of the National Cancer Institute magazine. The transfer is a major cause of mortality in cancer patients. "Triple negative" breast cancer patients with high-risk metastatic potential. In addition, breast cancer and prostate cancer are known to have variability, such as these types of tumors may be a long period of dormancy that this disease is silently lurking. Related factors induced or break the tumor cells dormant poorly understood, but it is clear that the extension of the tumor cells of Sleep is a cancer treatment strategy. In order to determine the impact of the the LPA1 inhibitor of metastatic cells dormant, the National Cancer Institute, Key Laboratory of Molecular Pharmacology, Jean-Claude A. Marshall, MSc, Ph.D., and colleagues in both the invasion of the "triple negative" breast cancer metastasis model system that mouse 4T1 breast cancer model and human MDA-MB-231 human breast cancer cell model analysis of the flavor of tumor size, distant metastasis and their molecular characteristics. The results showed that Debio-0719 or shRNA suppression LPA1 significantly inhibit the formation of metastases without affecting primary bit size of the tumor. Debio-0719 treated mice was found in remote organs, such as lung and liver cancer cells, but no longer have the proliferative capacity, molecular markers showing a dormant state. The authors noted that, no influence the LPA1 inhibitor on the primary bit in either tumor model of tumor growth. Accordingly, it usually will not be deemed to drugs to develop. Their data indicate that might develop new activity for example, can induce the dormant metastatic cells to enter the new compounds may have anti-tumor prospects.